Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Brain Cancer.
The Global Brain Cancer Market is projected to witness a compound annual growth rate (CAGR) of 10.03% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 5.39 billion in 2031.
The increasing prevalence of the disease in various regions across the globe is expected to boost the growth of the market. According to Global Information Research, the brain tumor drugs market size has grown from $3.55 billion in 2023 to $3.81 billion in 2024. The historical growth can be attributed to several factors, including a rising prevalence of neurological disorders, increased healthcare expenditure, a higher number of approvals for oncology drugs, an upsurge in pharmaceutical research and development (R&D) expenditure, and advancements in cancer drug discovery.
Forecasted growth is attributed to rising cancer rates, increased healthcare spending, a growing elderly population, a robust drug pipeline, and revised FDA regulations for biologics. Major trends include investing in drug combinations for brain tumor treatment, adopting phase zero clinical trials for efficacy improvement, focusing on expanding cell and gene therapy, and engaging in strategic mergers and acquisitions.
For additional information on Brain Cancer, please review the video by Medical Centric.